Midas Letter

Flora Growth Corp (NASDAQ:FLGC) is a brand new cannabis company but has already achieved significant milestones over its three-year history. The latest and perhaps the most notable being its recent NASDAQ listing and US$16.67 million capital raise. Flora Growth is leveraging its Colombian EU-GMP certified organic, outdoor growing facility with one of the best cost-structures in the […]

If you want to beat the stock market, one way to do it is to invest in the best sectors of the market. Although finding them can be tricky and due diligence is definitely required on investing in smaller companies within each emerging sector, there are lots of opportunities to be had! In this week’s […]

Bright Minds Biosciences Inc (CNSX:DRUG, OTCMKTS:BMBIF) is a biotech company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Our viewers may be familiar with GW Pharmaceuticals PLC (formerly NASDAQ:GWPH), recently acquired by Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), and its Epidiolex® (CBD) oral solution as a treatment for childhood-onset epilepsy. Bright Mind’s focus is on […]

Field Trip Health Ltd (TSE:FTRP, OTCMKTS:FTRPF) is the largest vertically integrated psychedelics company. Psychedelics are the first well-known contextual medicine (the experience a patient has when receiving the drug is almost equally important to the science behind the drug itself). Field Trip realizes this fact and is building the clinical infrastructure to deliver psychedelic therapies […]

Atai Life Sciences (NASDAQ:ATAI) is a mental health biotech company developing novel drugs (psychedelic and non-psychedelic) to cure various mental health diseases such as addiction, depression, anxiety, and PTSD. Atai recently raised $225 million in an upsized Nasdaq IPO. This impressive public offering values the company north of $2 billion. Why the excitement for another […]

It has been known anecdotally that psychedelics and magic mushrooms have had therapeutic effects. This set of “drugs” have been known to positively alter mindsets, enlighten consciousness. Now, they are finally getting the proper attention for actually helping mental health disorders such as depression. The 1960’s and the War on Drugs stunted any studies from […]

MYND Life Sciences (CNSX:MYND) is a company exploring anti-inflammatory benefits of psilocybin and other psychedelic compounds as they apply to depression and other central nervous system (CNS) disorders. There have been a lot of breakthroughs over the last decade defining what causes depression. Historically, depression has been diagnosed based on a checklist of symptoms system. […]

Health Logic Interactive Inc (CVE:CHIP.H, OTCMKTS:CHYPF) is developing point-of-care, lab-on-chip, digital diagnostic tools for screening of chronic kidney disease (CKD). Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Unfortunately, this condition is largely undiagnosed. In the early stages of chronic kidney disease, there may be few signs or […]

Awakn Life Sciences Corp (NEO:AWKN) is a biotechnology company with clinical operations developing and delivering the next generation of psychedelic medicines to treat addiction. According to a World Drug Report in 2019, 35 million people worldwide suffer from drug use disorders while only 1 in 7 people receive treatment. This number has likely increased during the tough times […]

Cryptocurrencies have exploded in perceived value in recent years. However, the most famous example Bitcoin (BTC), topping $64,000 in April, has now halved in value. The first chink in the armour came in May after promoter Elon Musk tweeted Tesla would stop using Bitcoin as a form of payment over concerns of the cryptocurrency’s impact on […]